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Abstract
AIM: To estimate the progression of the hepatitis C 
virus (HCV) epidemic and measure the burden of HCV-
related morbidity and mortality. 
METHODS: Age- and gender-defined cohorts were 
used to follow the viremic population in Argentina 
and estimate HCV incidence, prevalence, hepatic com-
plications, and mortality. The relative impact of two 
scenarios on HCV-related outcomes was assessed: (1) 
increased sustained virologic response (SVR); and (2) 
increased SVR and treatment.
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RESULTS: Under scenario 1, SVR raised to 85%-95% 
in 2016. Compared to the base case scenario, there 
was a 0.3% reduction in prevalent cases and liver-
related deaths by 2030. Given low treatment rates, 
cases of hepatocellular carcinoma and decompensated 
cirrhosis decreased < 1%, in contrast to the base case 
in 2030. Under scenario 2, the same increases in SVR 
were modeled, with gradual increases in the annual 
diagnosed and treated populations. This scenario 
decreased prevalent infections 45%, liver-related deaths 
55%, liver cancer cases 60%, and decompensated 
cirrhosis 55%, as compared to the base case by 2030. 
CONCLUSION: In Argentina, cases of end stage liver 
disease and liver-related deaths due to HCV are still 
growing, while its prevalence is decreasing. Increas-
ing in SVR rates is not enough, and increasing in the 
number of patients diagnosed and candidates for treat-
ment is needed to reduce the HCV disease burden. 
Based on this scenario, strategies to increase diagnosis 
and treatment uptake must be developed to reduce 
HCV burden in Argentina.
Key words: Diagnosis; Disease burden; Epidemiology; 
Incidence; Mortality; Prevalence; Treatment; Argentina; 
Hepatitis C
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Core tip: This is a study evaluating potential policies 
to diminish hepatitis C virus (HCV) disease burden. In-
creasing diagnoses and treated individuals with the high 
current sustained virologic response rates, will diminish 
HCV disease burden.
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INTRODUCTION
Chronic hepatitis C virus (HCV) liver disease is a global 
public health issue, with an estimated prevalence of 
170 million infected people. Every year, 3000000 to 
4000000 new HCV infections are diagnosed, and a 
mean global seroprevalence of nearly 3%[1]. 
In many countries, while HCV prevalence is de­
creasing, its morbidity and mortality is increasing[2]. 
Population aging results in a rise in all­cause mortality. 
This leads to a reduction in the total of infected patients. 
Progression to advanced HCV related liver disease 
combined with populace aging, is associated with a 
rising in mortality due to advanced liver disease[2,3].
In Argentina, the exact HCV prevalence is unknown. 
According to different studies it varies between 0.17% 
to 5.6%; in some areas of high endemicity it may vary 
between 2.2% to 7.3%[4]. Nosocomial transmission 
appears to be the main route of infection, and genotype 
1 is most prevalent in the infected population[5,6]. Precise 
data for incidence and prevalence estimates are lacking 
in Argentina. Also, there are no data about the burden of 
the disease and its impact on public health. Data on the 
percentage of HCV patients treated and their outcomes 
are also scarce. It has been estimated that only 0.15% 
of HCV patients have been treated in the last 15 years 
in Argentina[7]. These results are comparable to other 
countries in the region. Our aim was, using a modeling 
method, to describe HCV­related disease progression at 
the national level. 
A model was also used to evaluate the influence 
of distinct actions aimed at diminishing the burden of 
HCV disease (e.g., multiply the percentage of treated 
patients, improved cure rates and improved case identi­
fication). This model has been already validated and 
used in similar studies in different countries[8­11].
MATERIALS AND METHODS
A systematic review of the literature was done to find 
studies addressing the proportion of HCV patients who 
had been diagnosed, received treatment and achieve 
sustained virologic response (SVR) in Argentina. The 
review included all studies published between January 
1990 and July 2014. 
PubMed and EMBASE databases were consulted 
looking for indexed articles. Non­indexed sources were 
identified by searching in the National Ministry of Health
Website, proceedings of local medical meetings, unpub­
lished data and data from large liver centers. 
Also, an expert panel including epidemiologists, hepa­
tologists, infectious disease specialists, public health 
professionals and virologists, gathered in a person to 
person meeting to analyze all the retrieved information.
Data from countries with similar healthcare practices 
and/or risk factors, or expert consensus were used 
there was no input data available. Some of these data 
were included in a previous global report[2,3]. To populate 
a disease progression model and to assess the magni­
tude of the HCV­infected populace according to liver 
fibrosis stages (METAVIR score F0-F4), country-specific 
inputs from 2013­2030 were loaded in Microsoft Excel®
database (Microsoft Corp., Redmond, WA) (Figure 1). 
Crystal Ball, an Excel add­in by Oracle, was utilized for 
uncertainty and sensitivity analyses. For the uncertainty 
model, beta­PERT distributions were utilized associated 
with all inputs. To analyze the incertitudes that had the 
biggest repercussion on in 2030 HCV prevalence, a 
sensitivity analysis was utilized.
Populace information were arranged by sex, five­
year age groups, and year (1950­2100) and obtained 
from the United Nations population database[12]. Based 
on expert inputs, in adults (persons aged ≥ 20 years) 
HCV viremia prevalence in Argentina in 2013, was esti­
mated at 1.5%. The HCV viremic rate in Argentina is 
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80%, as previously reported[13]. 
Using a 0.83% viremic prevalence, it was calculated 
that 342000 persons had HCV RNA detectable in 2013.
A hybrid distribution was constructed to calculate age 
and gender specific HCV diagnosis rates by five­year 
age group using notification inputs for HCV infection for 
persons aged 0 to 59 years[14], and transplant inputs 
classified by age and gender for persons aged ≥ 60 
years[15]. The notified and transplanted people were 
weighted to the national estimate for total prevalence 
and aged to the year 2013, accounting for mortality and 
cured patients. 
To estimate HCV genotype distribution, data from 
over 200 treated patients was used[16]. Genotype 1 
(G1) subtypes distribution was calculated using data 
from another study[5]. The genotype distribution applied 
in the model was G1/other = 63%, G2 = 25%, G3 = 
11%, G4 = 1%. 
As outlined in a previous work, annual patients pro­
gress through each disease state were include in the 
model using age and gender specific transition proba-
bilities[2,3].
Changes in historical HCV incidence were estimated 
according to expert opinion. Changes in historical HCV 
incidence were estimated according to expert opinion. 
After an estimated peak incidence in 1989, it has 
markedly decrease with the introduction of antiHCV 
screening in blood donors. In Argentina, it was estimated 
that 1850 new infections were diagnosed in 2013.
It was estimated that 350 and 200 patients receive 
treatment in 2014 and 2015, respectively, based on 
expert consensus and IMS data for pegylated­interferon 
(IFN) units sold in Argentina[17]. A multiplier was used 
to account for under­reporting in IMS data. The Argen­
tinean genotype distribution was used to estimate the 
average number of weeks of treatment per patient with 
85% compliance/persistence.
In 2013, 74 of 329 (22.4%) patients receiving a 
liver transplant were related to HCV end stage liver 
disease. Data from the national organ registry for the 
years 1999 to 2013 showed that the percentage of liver 
transplant in HCV patients was 22.0% before adoption 
of model for end stage liver disease (MELD) based 
allocation and 22.4% after MELD implementation[15,16].
Database from the Pan American Health Organization 
allow us to estimate the diagnosed population based 
upon data for HCV positive blood donors[7]. The annual 
number of confirmed cases was balanced to account for 
diagnosis in other settings. It was assumed that 118800 
persons were previously diagnosed and 6560 new cases 
were confirmed in 2010. The Berkeley Human Mortality 
database was used to estimate mortality rate by year, 
age group and gender[18] (Table 1).
Using estimates of 65000 active injection drug users 
(IDU) and a 54.6% HCV prevalence in Argentina, it was 
calculated that in 2001, 9.3% of the HCV population 
were IDU[19,20].
Using a standard mortality ratio (SMR) of 10.0 for 
persons between 15 and 44 years old, a raised mortality 
was estimated among active IDU[21­26].
It was estimated that 20.8% of the HCV patients 
were related blood transfusions in 2005, according 
to data from a national study[6]. In this subgroup of 
patients, a SMR of 1.5 was applied for all age groups[27].
Scenarios
Base scenario: Patients aged 15­69 years were con­
sidered for treatment and 60% of potential patients 
in Argentina were considered candidates for antiHCV 
therapy. It was considered that median SVR rates 
were 60% (G1), 75% (G2/4), and 65% (G3). Treated 
populations of 350 patients in 2014 and 200 patients 
annually during 2015­2030 were modeled, was and 
were restricted to patients with fibrosis stages ≥ F3 (G1) 
and ≥ F2 (G2/3/4). 
It was considered that until 2016 patients with 
severe liver disease such as decompensated cirrhosis or 
eligible for transplantation, or those with hepatocellular 
carcinoma (HCC), were not candidates for treatment.
Scenario 1: Increased efficacy: It was assumed that 
by 2016, treatment eligibility raised to 95% for all geno­
types and SVR rates steadily raised to 90% (G1/4), 95% 
(G2), and 85% (G3). The number of patients treated 
and newly diagnosed every year remained constant, 
while treatment was extended to fibrosis stages ≥ F2 in 
all genotypes (Figure 2). 
Scenario 2: Increased efficacy and treatment: SVR, 
treatment eligibility, and fibrosis restriction increases 
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Figure 1  The flow of the hepatitis C virus disease progression model. HCC: Hepatocellular carcinoma.
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cirrhosis. By 2030, 2890 patients will die from HCV 
related liver disease in contrast to 1520 patients who 
died in 2013. The proportion of viremic patients who 
have compensated cirrhosis or decompensated cirrhosis 
or HCC will increase to 34% in 2030, as compared with 
14% in 2013 (Figures 5 and 6). 
New HCV treatment strategies imply an increase 
in SVR rates. Based on recent results SVR rates will 
increase to at least 90% (G1/4), 95% (G2), and 85% 
(G3) by 2016. In the same period, treatment eligibility 
will increase to 95% for all genotypes. According to the 
model, increasing treatment efficacy but keeping the 
same low number of treated patients (scenario 1) will 
result in 660 fewer viremic patients in 2030, a 0.3% 
reduction as compared to the base case. 
Compared with the base case, by 2030 it was 
estimated a 0.3% decrease in the number of HCC cases 
(2490 cases), a 0.3% decrease in liver related deaths 
(2880 cases), a 0.2% decrease in decompensated and 
0.3% in compensated cirrhosis new cases (7800 and 
69380 cases, respectively) (Figure 7).
Increased treatment efficacy alone seems to have 
little impact in decreasing HCV burden, so another 
scenario was developed with the same SVR rates but 
increasing numbers of patients diagnosed and treated 
(scenario 2). 
If the number of diagnosed and treated patients is 
markedly increased, a 45% reduction in the number 
of viremic patients can be obtained by 2030, meaning 
107000 fewer infected patients. A 60% reduction in 
HCC cases is expected, with 1000 new HCC cases 
diagnosed by 2030. It is expected that the number 
of liver related deaths will also decrease with 1260 by 
2030, meaning a 55% reduction when compared to the 
base case. New cirrhosis cases will decrease by 55% in 
decompensated and by 60% in compensated cases by 
2030 (3390 and 29210, respectively) (Figure 7).
were the same as in scenario 1. The number of patients 
newly diagnosed every year progressively escalated to 
14770 in 2016, while the number of patients treated 
every year progressively escalated to 12000 by 2020 
(Figure 3).
RESULTS
Prevalence of chronic hepatitis C and complications
According to the model, the HCV prevalence in Argen­
tina peaked in 2002 at 376000 viremic individuals. 
In 2013, there were an estimated 342000 (95%CI: 
146000­517000) infected individuals, a 10% decline 
from 2002. In the base scenario, viremic cases are esti­
mated at 241000 in 2030, a decline of 30% from 2014 
(Figure 4). The incidence of HCV in Argentina peaked 
in 1989 with an estimated 21340 new infections, and 
declined by 90% in 2013 with an estimated 1850 cases 
new infections.
There were 42910 compensated cirrhotic patients 
in 2013 and it was calculated that there will be 69600 
by 2030. Also by 2030 there will be 2500 new cases 
of HCC 7830 patients will develop decompensated 
Table 1  Model inputs and 2013 estimates
Historical Year 2013 (Est.)
HCV infected cases    427890 (132720-829480) 2013 428260
   AntiHCV prevalence 1.0% (0.3%-2.0%)           1.0%
   Total viremic cases    342310 (106170-663580) 2013 342310
   Viremic prevalence 0.8% (0.3%-1.6%)           0.8%
   Viremic rate         80.0%         80.0%
HCV diagnosed (viremic) 112270 2010 117250
   Viremic diagnosis rate         32.8%         34.2%
   Annual newly diagnosed     4920 2010     4920
New infections     1950
   New infection rate (per 100K)        4.7
Treated
   Number treated       650
   Annual treatment rate           0.2%
Risk factors
   Number of active IDU with HCV   31950
   Percent active IDU           9.3%
   Previous blood transfusion   48420
   Percent previous blood transfusion         14.1%
HCV: Hepatitis C virus; IDU: Injection drug users.
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DISCUSSION
Increasing access to HCV diagnosis and treatment are 
pending actions in Argentina and in Latin­America. It 
is estimated that less than 20%­30% of patients are 
diagnosed and only 1%­2% of those diagnosed have 
been treated[7]. Approval of new HCV treatments in 
the region is delayed compared with Europe or the 
United States. In the last months of 2015, three novel 
regimens were approved in Argentina. Upcoming IFN 
and ribavirin free regimens are safe and effective, 
offering SVR rates over 90%­95% for most genotypes. 
To impact the burden of disease, patients must be 
diagnosed and treatment availability must increase.
Our study shows important results for our country. 
The greatest burden of HCV­related advanced liver 
disease will come in the next 5 to 15 years. HCV burden 
will increase if no action is taken. Our model showed 
that the only way to significantly reduce HCV burden is 
to increase diagnosed and treated patients 10 times the 
current number of treated persons. Similar results have 
been reported in many countries around the world, 
including some in Latin­America, including Brazil and 
Mexico[2,3]. 
The main challenge in the region is to develop 
strategies to increase diagnosis. Strategies must be 
country specific since epidemiology and risk factors for 
HCV infection vary between countries. For example, 
the United States Centers for Disease Control and 
Prevention has recommended a birth­year based screen­
ing strategy: Persons born during 1945­1965 in the 
United States have an increased rate of HCV infection 
and focused screening of this cohort is an efficient use 
of resources[28]. But this strategy might not be effective 
in Argentina, since in 2013 the majority of HCV patients 
are estimated to be 40 to 75 years old (Figure 2), 
meaning that they were born between 1938 and 1973. 
The same was shown in Brazil where most patients 
were born between 1950 and 1980[29]. Country specific 
screening campaigns must be developed to achieve this 
goal.
Another pending issue is adequate access to care 
and treatment. This means that all people involved in 
HCV management must make an effort to achieve this 
goal. Patients need greater access to new therapies, 
but the main restriction is treatment cost. In resource 
constrained countries, treating all patients with current 
drug costs is unaffordable. There must be strategies to 
reduce HCV treatment costs and at the beginning, pri­
oritization of treatment may be necessary. For example, 
the sickest patients will be treated first with the safest 
and more effective drugs. Then earlier stage patients will 
be treated later to reduce the impact of the disease.
This is the first study evaluating HCV burden in Arg-
entina. These results might help public health authorities 
take action to reduce its impact. But it has to be 
mentioned that our results have some limitations. 
First, each input may have its limitations, but to 
our knowledge the best data from published and unpu­
blished studies available in Argentina were applied in our 
model. Second, some patients may have progressive 
liver disease despite achieving SVR; progression of 
cured patients was not evaluated in this model[30]. And 
finally, we did not include extrahepatic manifestations of 
HCV infection in the model, which may had contribute to 
all­cause mortality and may lead to underestimation in 
mortality among viremic patients[9].
In conclusion, the present analysis, with the available 
data, showed that HCV prevalence is decreasing in 
Argentina, but advanced liver disease prevalence is 
expected to raise as HCV infected patients get older. 
There is an urgent need to enhance diagnosis and 
treatment rates to reduce the future disease burden and 
its impact on Argentina’s public health.
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